Related Experiment Videos
Methadone for treatment of cancer pain
John Bryson1, Anoo Tamber, Dori Seccareccia
1Division of Medical Oncology and Hematology, Psychosocial Oncology and Palliative Care Program, Princess Margaret Hospital, Toronto, Ontario, Canada M5G 2M9.
Abstract:
Methadone is a unique mu opioid agonist, which also has delta receptor affinity and properties of N-methyl-D-aspartate receptor antagonism and monoamine reuptake inhibition. It is mainly used in the setting of uncontrolled pain or dose-limiting toxicity. Caution is advised when switching to methadone, especially from high doses of previous opioid, due to its variable conversion ratio and the potential for delayed toxicity due to its long half-life. Increasing evidence of risk also exists for a prolonged QT interval and torsades de pointes with very large doses of methadone. Methadone is likely safer when used at lower doses as a first-line opioid, but its potential as such has not received enough formal evaluation. Randomized controlled trials are needed to assess the effectiveness and safety of methadone compared with other opioids and to further evaluate its role in the treatment of neuropathic pain.
Insights
Methadone, a unique opioid agonist, offers pain relief but requires caution due to its long half-life and potential for delayed toxicity. Further research is needed to evaluate its safety and effectiveness as a first-line pain medication.
Area of Science:
- Pharmacology
- Pain Management
- Clinical Therapeutics
Background:
- Methadone is a mu opioid agonist with additional N-methyl-D-aspartate receptor antagonist and monoamine reuptake inhibitor properties.
- It is primarily indicated for uncontrolled pain or opioid dose-limiting toxicities.
Purpose of the Study:
- To review the unique pharmacological profile of methadone.
- To highlight clinical considerations for methadone use, including switching from other opioids and potential toxicities.
- To emphasize the need for further research into methadone's role in pain management.
Main Methods:
- Literature review of methadone's pharmacological actions and clinical applications.
- Analysis of safety data, including conversion ratios, half-life, and QT interval prolongation.
- Identification of research gaps regarding methadone's efficacy and safety.
Main Results:
- Methadone exhibits complex pharmacology beyond mu opioid agonism.
- Switching to methadone requires careful consideration due to variable conversion and delayed toxicity risks.
- Large doses of methadone are associated with QT interval prolongation and torsades de pointes.
Conclusions:
- Methadone's unique properties necessitate cautious use, especially when transitioning from other opioids.
- Lower doses of methadone may offer a safer profile, but require further evaluation.
- Randomized controlled trials are essential to determine methadone's comparative effectiveness and safety in neuropathic pain and as a first-line agent.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Analgesia and Pain Management
Opioid Analgesics: Morphine and Other Natural Cogeners
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Treatment Resistant Cancers